Silo Pharma于2026年8月18日与Parkview Consulting达成资产购买协议。此消息源自公司向美国证券交易委员会（SEC）提交的官方文件。
这一战略举措标志着Silo Pharma在业务布局上的重要一步。协议签署的细节已在监管文件中完整呈现。
市场参与者对此交易的反应尚待观察。Silo Pharma的这一决策，可能预示着公司在资产组合优化方面的新动向。SEC文件为该协议的条款提供了正式记录，确保交易的透明度。
截至发稿时，Silo Pharma尚未就协议的具体财务条款和涉及的资产类别发表进一步评论。此次合作或将影响公司未来的发展方向，值得持续关注。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.